0
Upcoming Allied Market Research
2023
Neglected Tropical Diseases Market

Neglected Tropical Diseases Market: Global Opportunity Analysis and Industry Forecast, 2019-2027 Market

Report Code: A10541
Nov 2023 | Pages: NA
Tables: NA
Charts: NA
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Neglected Tropical Diseases Market

Request Now !

Neglected tropical diseases (NTDs) are a diverse group of communicable diseases that prevail in tropical and subtropical conditions in 149 countries, which affect more than one billion people and cost developing economies billions of dollars every year. NTDs such as dengue, lymphatic filariasis, trachoma, and leishmaniasis are called neglected, as they generally afflict the world's poor and historically have not received as much attention as other diseases. NTDs tend to thrive in developing regions of the world, where water quality, sanitation, and access to healthcare are substandard. However, some of these diseases are prevalent in areas of the U.S. with high rates of poverty.

COVID-19 scenario analysis: 

Pharmaceutical and biotechnological companies together with governments around the globe are working to combat with the COVID-19 outbreak, from supporting the development of vaccines to schedule for medicines supply chain challenges. Furthermore, there are around 115 vaccine candidates and other 155 molecules that are kept in the R&D pipeline in the coming years. Moreover, commonly used drugs such as hydroxychloroquine have seen huge boost in demand for the management of COVID-19. Increase in demand for drugs has been witnessed, which is likely to offer lucrative opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.

Top impacting factors: market scenario analysis, trends, drivers, and impact analysis

The major factor affecting the industry includes formal recognition of NTDs in the Sustainable Development Goals (SDG), a United Nations Development Programme, as a global target is expected to help the industry gain traction during the forecast period. Furthermore, surge in the number of programs, which are helpful to tackle NTDs is expected to propel the neglected tropical diseases market growth in the next few years. Various R&D programs are conducted that are useful for helping the healthcare industry to completely focus over the cost-efficient therapeutics, which would help the market flourish in the coming years. 

Rise in the product launches 

Increase in the product launches is expected to fuel the neglected tropical diseases market growth in the coming years. For instance, in February 2019, Novartis announced that the U.S. Food and Drug Administration (FDA) approved Egaten (triclabendazole) for the treatment of fascioliasis in patients six years of age and older. This makes Egaten the only FDA-approved drug for people with this disease, and is expected to facilitate broader access to this important drug not only in the U.S. but also in affected countries worldwide. R&D in the neglected tropical diseases treatment would help the industry to grow at a significant rate in the coming years.

Surge in number of mergers and acquisitions 

Increase in the mergers and acquisitions would help the companies gain maximum attention of the population and help the industry to flourish in the next few years. For instance, in April 2017, Merck, a leading science and technology company, announced collaboration with Drugs for Neglected Diseases initiative (DNDi) to accelerate the research process and reduce costs in finding new treatments for neglected tropical diseases leishmaniasis and Chagas disease, which 450 million people are at risk of contracting. 

DNDi is a collaborative, patient-needs-driven, non-profit drug R&D organization for neglected diseases. Through the collaboration with DNDi, Merck is working with a network of leading, internationally recognized experts in this area. In addition, Merck is supporting local R&D capacity-building via DNDi’s network of centers of expertise in R&D for NTDs in the global north and global south. A collaboration with five other pharmaceutical companies (Eisai, Shionogi, Takeda, AstraZeneca, and Celgene), the DNDi NTD Booster experiments with a new open-innovation approach to drug discovery through a multilateral, simultaneous search process across the member companies.

Key benefits of the report:

  • This study presents the analytical depiction of the global neglected tropical diseases industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global neglected tropical diseases market share.
  • The current market is quantitatively analyzed to highlight the neglected tropical diseases market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years. 

Questions answered in the global neglected tropical diseases market research report:

  • Which are the leading players active in the global neglected tropical diseases market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the neglected tropical diseases market?
  • What are the projections for the future that would help in tasking further strategic steps?

Neglected Tropical Diseases Market: Global Opportunity Analysis and Industry Forecast, 2019–2027 Report Highlights

Aspects Details
By Diseases Type
  • Buruli Ulcer
  • Yaws
  • Leprosy
  • Dengue
  • Rabies
  • Trachoma
  • Chagas Disease
  • Human African Trypanosomiasis (Sleeping Sickness)
  • Leishmaniases
  • Soil-Transmitted Helminthiases
  • Others
By Product Type
  • Drug
  • Vaccines
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Gilead Sciences,, Pfizer, Inc.,, Takeda Pharmaceutical Company Limited, Astellas Pharma,, Eisai Co., Ltd.,, Novartis AG,, Sanofi,, Bayer AG,, F. Hoffmann La Roche Ltd,, GlaxoSmithKline plc,
 
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: NEGLECTED TROPICAL DISEASES MARKET, BY DISEASES TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Diseases Type

    • 4.2. Buruli Ulcer

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Yaws

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Leprosy

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Dengue

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Rabies

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Trachoma

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

    • 4.8. Chagas Disease

      • 4.8.1. Key Market Trends, Growth Factors and Opportunities

      • 4.8.2. Market Size and Forecast, By Region

      • 4.8.3. Market Share Analysis, By Country

    • 4.9. Human African Trypanosomiasis (Sleeping Sickness)

      • 4.9.1. Key Market Trends, Growth Factors and Opportunities

      • 4.9.2. Market Size and Forecast, By Region

      • 4.9.3. Market Share Analysis, By Country

    • 4.10. Leishmaniases

      • 4.10.1. Key Market Trends, Growth Factors and Opportunities

      • 4.10.2. Market Size and Forecast, By Region

      • 4.10.3. Market Share Analysis, By Country

    • 4.11. Soil-Transmitted Helminthiases

      • 4.11.1. Key Market Trends, Growth Factors and Opportunities

      • 4.11.2. Market Size and Forecast, By Region

      • 4.11.3. Market Share Analysis, By Country

    • 4.12. Others

      • 4.12.1. Key Market Trends, Growth Factors and Opportunities

      • 4.12.2. Market Size and Forecast, By Region

      • 4.12.3. Market Share Analysis, By Country

  • CHAPTER 5: NEGLECTED TROPICAL DISEASES MARKET, BY PRODUCT TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Product Type

    • 5.2. Drug

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Vaccines

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: NEGLECTED TROPICAL DISEASES MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Diseases Type

      • 6.2.3. Market Size and Forecast, By Product Type

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Neglected Tropical Diseases Market

        • 6.2.5.1. Market Size and Forecast, By Diseases Type
        • 6.2.5.2. Market Size and Forecast, By Product Type
      • 6.2.6. Canada Neglected Tropical Diseases Market

        • 6.2.6.1. Market Size and Forecast, By Diseases Type
        • 6.2.6.2. Market Size and Forecast, By Product Type
      • 6.2.7. Mexico Neglected Tropical Diseases Market

        • 6.2.7.1. Market Size and Forecast, By Diseases Type
        • 6.2.7.2. Market Size and Forecast, By Product Type
    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Diseases Type

      • 6.3.3. Market Size and Forecast, By Product Type

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Neglected Tropical Diseases Market

        • 6.3.5.1. Market Size and Forecast, By Diseases Type
        • 6.3.5.2. Market Size and Forecast, By Product Type
      • 6.3.6. Germany Neglected Tropical Diseases Market

        • 6.3.6.1. Market Size and Forecast, By Diseases Type
        • 6.3.6.2. Market Size and Forecast, By Product Type
      • 6.3.7. Italy Neglected Tropical Diseases Market

        • 6.3.7.1. Market Size and Forecast, By Diseases Type
        • 6.3.7.2. Market Size and Forecast, By Product Type
      • 6.3.8. Spain Neglected Tropical Diseases Market

        • 6.3.8.1. Market Size and Forecast, By Diseases Type
        • 6.3.8.2. Market Size and Forecast, By Product Type
      • 6.3.9. UK Neglected Tropical Diseases Market

        • 6.3.9.1. Market Size and Forecast, By Diseases Type
        • 6.3.9.2. Market Size and Forecast, By Product Type
      • 6.3.10. Russia Neglected Tropical Diseases Market

        • 6.3.10.1. Market Size and Forecast, By Diseases Type
        • 6.3.10.2. Market Size and Forecast, By Product Type
      • 6.3.11. Rest Of Europe Neglected Tropical Diseases Market

        • 6.3.11.1. Market Size and Forecast, By Diseases Type
        • 6.3.11.2. Market Size and Forecast, By Product Type
    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Diseases Type

      • 6.4.3. Market Size and Forecast, By Product Type

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Neglected Tropical Diseases Market

        • 6.4.5.1. Market Size and Forecast, By Diseases Type
        • 6.4.5.2. Market Size and Forecast, By Product Type
      • 6.4.6. Japan Neglected Tropical Diseases Market

        • 6.4.6.1. Market Size and Forecast, By Diseases Type
        • 6.4.6.2. Market Size and Forecast, By Product Type
      • 6.4.7. India Neglected Tropical Diseases Market

        • 6.4.7.1. Market Size and Forecast, By Diseases Type
        • 6.4.7.2. Market Size and Forecast, By Product Type
      • 6.4.8. South Korea Neglected Tropical Diseases Market

        • 6.4.8.1. Market Size and Forecast, By Diseases Type
        • 6.4.8.2. Market Size and Forecast, By Product Type
      • 6.4.9. Australia Neglected Tropical Diseases Market

        • 6.4.9.1. Market Size and Forecast, By Diseases Type
        • 6.4.9.2. Market Size and Forecast, By Product Type
      • 6.4.10. Thailand Neglected Tropical Diseases Market

        • 6.4.10.1. Market Size and Forecast, By Diseases Type
        • 6.4.10.2. Market Size and Forecast, By Product Type
      • 6.4.11. Malaysia Neglected Tropical Diseases Market

        • 6.4.11.1. Market Size and Forecast, By Diseases Type
        • 6.4.11.2. Market Size and Forecast, By Product Type
      • 6.4.12. Indonesia Neglected Tropical Diseases Market

        • 6.4.12.1. Market Size and Forecast, By Diseases Type
        • 6.4.12.2. Market Size and Forecast, By Product Type
      • 6.4.13. Rest of Asia Pacific Neglected Tropical Diseases Market

        • 6.4.13.1. Market Size and Forecast, By Diseases Type
        • 6.4.13.2. Market Size and Forecast, By Product Type
    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Diseases Type

      • 6.5.3. Market Size and Forecast, By Product Type

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Neglected Tropical Diseases Market

        • 6.5.5.1. Market Size and Forecast, By Diseases Type
        • 6.5.5.2. Market Size and Forecast, By Product Type
      • 6.5.6. South Africa Neglected Tropical Diseases Market

        • 6.5.6.1. Market Size and Forecast, By Diseases Type
        • 6.5.6.2. Market Size and Forecast, By Product Type
      • 6.5.7. Saudi Arabia Neglected Tropical Diseases Market

        • 6.5.7.1. Market Size and Forecast, By Diseases Type
        • 6.5.7.2. Market Size and Forecast, By Product Type
      • 6.5.8. UAE Neglected Tropical Diseases Market

        • 6.5.8.1. Market Size and Forecast, By Diseases Type
        • 6.5.8.2. Market Size and Forecast, By Product Type
      • 6.5.9. Argentina Neglected Tropical Diseases Market

        • 6.5.9.1. Market Size and Forecast, By Diseases Type
        • 6.5.9.2. Market Size and Forecast, By Product Type
      • 6.5.10. Rest of LAMEA Neglected Tropical Diseases Market

        • 6.5.10.1. Market Size and Forecast, By Diseases Type
        • 6.5.10.2. Market Size and Forecast, By Product Type
  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. F. Hoffmann La Roche Ltd,

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Bayer AG,

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. GlaxoSmithKline Plc,

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Novartis AG,

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Pfizer, Inc.,

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Eisai Co., Ltd.,

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Sanofi,

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Astellas Pharma,

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Gilead Sciences,

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Takeda Pharmaceutical Company Limited

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL NEGLECTED TROPICAL DISEASES MARKET, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL NEGLECTED TROPICAL DISEASES MARKET FOR BURULI ULCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL NEGLECTED TROPICAL DISEASES MARKET FOR YAWS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL NEGLECTED TROPICAL DISEASES MARKET FOR LEPROSY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL NEGLECTED TROPICAL DISEASES MARKET FOR DENGUE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL NEGLECTED TROPICAL DISEASES MARKET FOR RABIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL NEGLECTED TROPICAL DISEASES MARKET FOR TRACHOMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL NEGLECTED TROPICAL DISEASES MARKET FOR CHAGAS DISEASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL NEGLECTED TROPICAL DISEASES MARKET FOR HUMAN AFRICAN TRYPANOSOMIASIS (SLEEPING SICKNESS), BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL NEGLECTED TROPICAL DISEASES MARKET FOR LEISHMANIASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL NEGLECTED TROPICAL DISEASES MARKET FOR SOIL-TRANSMITTED HELMINTHIASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL NEGLECTED TROPICAL DISEASES MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL NEGLECTED TROPICAL DISEASES MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL NEGLECTED TROPICAL DISEASES MARKET FOR DRUG, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL NEGLECTED TROPICAL DISEASES MARKET FOR VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL NEGLECTED TROPICAL DISEASES MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA NEGLECTED TROPICAL DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 20. U.S. NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 21. U.S. NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 22. CANADA NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 23. CANADA NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE NEGLECTED TROPICAL DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 29. FRANCE NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 30. FRANCE NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 33. ITALY NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 34. ITALY NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 35. SPAIN NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 36. SPAIN NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 37. UK NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 38. UK NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 39. RUSSIA NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 40. RUSSIA NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 41. REST OF EUROPE NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 42. REST OF EUROPE NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 43. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 44. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 45. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 46. CHINA NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 47. CHINA NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 48. JAPAN NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 49. JAPAN NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 50. INDIA NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 51. INDIA NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 52. SOUTH KOREA NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 53. SOUTH KOREA NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 54. AUSTRALIA NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 55. AUSTRALIA NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 56. THAILAND NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 57. THAILAND NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 58. MALAYSIA NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 59. MALAYSIA NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 60. INDONESIA NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 61. INDONESIA NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 62. REST OF ASIA PACIFIC NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 63. REST OF ASIA PACIFIC NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 64. LAMEA NEGLECTED TROPICAL DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 65. LAMEA NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 66. LAMEA NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 67. BRAZIL NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 68. BRAZIL NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH AFRICA NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 70. SOUTH AFRICA NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 71. SAUDI ARABIA NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 72. SAUDI ARABIA NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 73. UAE NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 74. UAE NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 75. ARGENTINA NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 76. ARGENTINA NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 77. REST OF LAMEA NEGLECTED TROPICAL DISEASES, BY DISEASES TYPE, 2022-2032 ($MILLION)
  • TABLE 78. REST OF LAMEA NEGLECTED TROPICAL DISEASES, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 79. F. HOFFMANN LA ROCHE LTD,: KEY EXECUTIVES
  • TABLE 80. F. HOFFMANN LA ROCHE LTD,: COMPANY SNAPSHOT
  • TABLE 81. F. HOFFMANN LA ROCHE LTD,: OPERATING SEGMENTS
  • TABLE 82. F. HOFFMANN LA ROCHE LTD,: PRODUCT PORTFOLIO
  • TABLE 83. F. HOFFMANN LA ROCHE LTD,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84. BAYER AG,: KEY EXECUTIVES
  • TABLE 85. BAYER AG,: COMPANY SNAPSHOT
  • TABLE 86. BAYER AG,: OPERATING SEGMENTS
  • TABLE 87. BAYER AG,: PRODUCT PORTFOLIO
  • TABLE 88. BAYER AG,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 89. GLAXOSMITHKLINE PLC,: KEY EXECUTIVES
  • TABLE 90. GLAXOSMITHKLINE PLC,: COMPANY SNAPSHOT
  • TABLE 91. GLAXOSMITHKLINE PLC,: OPERATING SEGMENTS
  • TABLE 92. GLAXOSMITHKLINE PLC,: PRODUCT PORTFOLIO
  • TABLE 93. GLAXOSMITHKLINE PLC,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 94. NOVARTIS AG,: KEY EXECUTIVES
  • TABLE 95. NOVARTIS AG,: COMPANY SNAPSHOT
  • TABLE 96. NOVARTIS AG,: OPERATING SEGMENTS
  • TABLE 97. NOVARTIS AG,: PRODUCT PORTFOLIO
  • TABLE 98. NOVARTIS AG,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 99. PFIZER, INC.,: KEY EXECUTIVES
  • TABLE 100. PFIZER, INC.,: COMPANY SNAPSHOT
  • TABLE 101. PFIZER, INC.,: OPERATING SEGMENTS
  • TABLE 102. PFIZER, INC.,: PRODUCT PORTFOLIO
  • TABLE 103. PFIZER, INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 104. EISAI CO., LTD.,: KEY EXECUTIVES
  • TABLE 105. EISAI CO., LTD.,: COMPANY SNAPSHOT
  • TABLE 106. EISAI CO., LTD.,: OPERATING SEGMENTS
  • TABLE 107. EISAI CO., LTD.,: PRODUCT PORTFOLIO
  • TABLE 108. EISAI CO., LTD.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. SANOFI,: KEY EXECUTIVES
  • TABLE 110. SANOFI,: COMPANY SNAPSHOT
  • TABLE 111. SANOFI,: OPERATING SEGMENTS
  • TABLE 112. SANOFI,: PRODUCT PORTFOLIO
  • TABLE 113. SANOFI,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. ASTELLAS PHARMA,: KEY EXECUTIVES
  • TABLE 115. ASTELLAS PHARMA,: COMPANY SNAPSHOT
  • TABLE 116. ASTELLAS PHARMA,: OPERATING SEGMENTS
  • TABLE 117. ASTELLAS PHARMA,: PRODUCT PORTFOLIO
  • TABLE 118. ASTELLAS PHARMA,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. GILEAD SCIENCES,: KEY EXECUTIVES
  • TABLE 120. GILEAD SCIENCES,: COMPANY SNAPSHOT
  • TABLE 121. GILEAD SCIENCES,: OPERATING SEGMENTS
  • TABLE 122. GILEAD SCIENCES,: PRODUCT PORTFOLIO
  • TABLE 123. GILEAD SCIENCES,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 124. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY EXECUTIVES
  • TABLE 125. TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
  • TABLE 126. TAKEDA PHARMACEUTICAL COMPANY LIMITED: OPERATING SEGMENTS
  • TABLE 127. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
  • TABLE 128. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL NEGLECTED TROPICAL DISEASES MARKET SEGMENTATION
  • FIGURE 2. GLOBAL NEGLECTED TROPICAL DISEASES MARKET
  • FIGURE 3. SEGMENTATION NEGLECTED TROPICAL DISEASES MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN NEGLECTED TROPICAL DISEASES MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALNEGLECTED TROPICAL DISEASES MARKET
  • FIGURE 11. NEGLECTED TROPICAL DISEASES MARKET SEGMENTATION, BY BY DISEASES TYPE
  • FIGURE 12. NEGLECTED TROPICAL DISEASES MARKET FOR BURULI ULCER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. NEGLECTED TROPICAL DISEASES MARKET FOR YAWS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. NEGLECTED TROPICAL DISEASES MARKET FOR LEPROSY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. NEGLECTED TROPICAL DISEASES MARKET FOR DENGUE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. NEGLECTED TROPICAL DISEASES MARKET FOR RABIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. NEGLECTED TROPICAL DISEASES MARKET FOR TRACHOMA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. NEGLECTED TROPICAL DISEASES MARKET FOR CHAGAS DISEASE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. NEGLECTED TROPICAL DISEASES MARKET FOR HUMAN AFRICAN TRYPANOSOMIASIS (SLEEPING SICKNESS), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. NEGLECTED TROPICAL DISEASES MARKET FOR LEISHMANIASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. NEGLECTED TROPICAL DISEASES MARKET FOR SOIL-TRANSMITTED HELMINTHIASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. NEGLECTED TROPICAL DISEASES MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. NEGLECTED TROPICAL DISEASES MARKET SEGMENTATION, BY BY PRODUCT TYPE
  • FIGURE 24. NEGLECTED TROPICAL DISEASES MARKET FOR DRUG, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. NEGLECTED TROPICAL DISEASES MARKET FOR VACCINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 27. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 28. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 29. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 30. COMPETITIVE DASHBOARD
  • FIGURE 31. COMPETITIVE HEATMAP: NEGLECTED TROPICAL DISEASES MARKET
  • FIGURE 32. Top player positioning, 2022
  • FIGURE 33. F. HOFFMANN LA ROCHE LTD,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. F. HOFFMANN LA ROCHE LTD,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. F. HOFFMANN LA ROCHE LTD,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. BAYER AG,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. BAYER AG,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. BAYER AG,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. GLAXOSMITHKLINE PLC,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. GLAXOSMITHKLINE PLC,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. GLAXOSMITHKLINE PLC,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. NOVARTIS AG,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. NOVARTIS AG,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. NOVARTIS AG,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. PFIZER, INC.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. PFIZER, INC.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. PFIZER, INC.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. EISAI CO., LTD.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. EISAI CO., LTD.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. EISAI CO., LTD.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. SANOFI,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. SANOFI,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. SANOFI,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. ASTELLAS PHARMA,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. ASTELLAS PHARMA,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. ASTELLAS PHARMA,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. GILEAD SCIENCES,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. GILEAD SCIENCES,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. GILEAD SCIENCES,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 60. TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. TAKEDA PHARMACEUTICAL COMPANY LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 62. TAKEDA PHARMACEUTICAL COMPANY LIMITED: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Neglected Tropical Diseases Market

Start reading.
This Report and over 67,132+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers